ESMO
AstraZeneca’s Tagrisso beats standard of care in halting NSCLC
September 11, 2017Research and Development, Sales and Marketing AstraZeneca, ESMO, NSCLC, Tagrisso, non-small cell cell cancer, pharma, pharmaceutical
AstraZeneca has revealed new data at the European Society of Medical Oncology (ESMO) on the efficacy of Tagrisso (osimertinib) in …
Merck says its Erbitux in combination with Folfox improves outcomes in colorectal cancer
July 4, 2016Research and Development, Sales and Marketing Cancer, China, ESMO, Merck, colorectal cancer, drug trial, research, study
Merck said late-stage trials for its Erbitux (cetuximab) in combination with Folfox significantly improved progression free survival in metastatic colorectal …
Roche’s Perjeta sees ‘impressive’ survival rates
September 29, 2014Sales and Marketing Cancer, ESMO, Perjeta, Roche, breast, madrid
Roche’s oncology drug Perjeta combined with other medicines can help certain breast cancer patients live longer. This is according to …
Europe warned over cancer research risk
July 27, 2014Medical Communications, Research and Development, Sales and Marketing ESMO, EU, Macmillan, data
A leading European doctors’ group is warning that new data protection rules could make cancer research ‘impossible’ whilst also adding …
Pharma unprepared for personalised oncology
November 29, 2010Research and Development, Sales and Marketing Cancer, ESMO, ESMO Cancer Biology for Clinicians Symposium, oncology, personalised medicine
The new era of personalised cancer care requires different thinking from pharma companies, according to experts at the ESMO symposium. …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
